Health Care·Biotechnology·$2.2B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.19 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.19 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed caution regarding future performance without providing specific guidance. They emphasized their commitment to advancing clinical programs.
Management did not provide specific revenue guidance for the upcoming quarters.
The focus remains on ongoing clinical trials and product development.
The earnings report reflects ongoing challenges for Biocryst Pharmaceuticals, particularly in terms of profitability, as indicated by the negative EPS. The stock reacted negatively, dropping 10.59%, likely due to the lack of revenue information and guidance. Investors may be concerned about the company's future performance without clear direction from management.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
SBA COMMUNICATIONS C Class A REIT
May 1, 2017